Literature DB >> 23529000

Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Lois B Travis1, Wendy Demark Wahnefried, James M Allan, Marie E Wood, Andrea K Ng.   

Abstract

Second and higher-order malignancies now comprise about 18% of all incident cancers in the USA, superseding first primary cancers of the breast, lung, and prostate. The occurrence of second malignant neoplasms (SMN) is influenced by a myriad of factors, including the late effects of cancer therapy, shared aetiological factors with the primary cancer (such as tobacco use, excessive alcohol intake, and obesity), genetic predisposition, environmental determinants, host effects, and combinations of factors, including gene-environment interactions. The influence of these factors on SMN in survivors of adult-onset cancer is reviewed here. We also discuss how modifiable behavioural and lifestyle factors may contribute to SMN, and how these factors can be managed. Cancer survivorship provides an opportune time for oncologists and other health-care providers to counsel patients with regard to health promotion, not only to reduce SMN risk, but to minimize co-morbidities. In particular, the importance of smoking cessation, weight control, physical activity, and other factors consonant with adoption of a healthy lifestyle should be consistently emphasized to cancer survivors. Clinicians can also play a critical role by endorsing genetic counselling for selected patients and making referrals to dieticians, exercise trainers, and others to assist with lifestyle change interventions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529000     DOI: 10.1038/nrclinonc.2013.41

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  196 in total

1.  Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study.

Authors:  Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan
Journal:  Ann Intern Med       Date:  2012-06-05       Impact factor: 25.391

2.  Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party.

Authors:  Debra L Friedman; Alicia Rovo; Wendy Leisenring; Anna Locasciulli; Mary E D Flowers; Andre Tichelli; Jean E Sanders; H Joachim Deeg; Gerard Socie
Journal:  Blood       Date:  2007-10-02       Impact factor: 22.113

3.  The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.

Authors:  Marianne Berwick; Irene Orlow; Amanda J Hummer; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton-Culver; Roberto Zanetti; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Peter A Kanetsky; Klaus Busam; Lynn From; Urvi Mujumdar; Homer Wilcox; Colin B Begg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

Review 4.  A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy?

Authors:  C Nutting; R S Camplejohn; R Gilchrist; D Tait; P Blake; G Knee; W Q Yao; G Ross; C Fisher; R Eeles
Journal:  Clin Oncol (R Coll Radiol)       Date:  2000       Impact factor: 4.126

5.  Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation.

Authors:  D W Milligan; M C Ruiz De Elvira; H J Kolb; A H Goldstone; G Meloni; A Z Rohatiner; P Colombat; N Schmitz
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

6.  IRF4 variants have age-specific effects on nevus count and predispose to melanoma.

Authors:  David L Duffy; Mark M Iles; Dan Glass; Gu Zhu; Jennifer H Barrett; Veronica Höiom; Zhen Z Zhao; Richard A Sturm; Nicole Soranzo; Chris Hammond; Marina Kvaskoff; David C Whiteman; Massimo Mangino; Johan Hansson; Julia A Newton-Bishop; Veronique Bataille; Nicholas K Hayward; Nicholas G Martin; D Timothy Bishop; Timothy D Spector; Grant W Montgomery
Journal:  Am J Hum Genet       Date:  2010-06-17       Impact factor: 11.025

7.  Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer.

Authors:  Elizabeth L Kaufman; Judith S Jacobson; Dawn L Hershman; Manisha Desai; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

Review 8.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.

Authors:  Catherine de Martel; Jacques Ferlay; Silvia Franceschi; Jérôme Vignat; Freddie Bray; David Forman; Martyn Plummer
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

Review 9.  The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma.

Authors:  D G Evans; P A Farndon; L D Burnell; H R Gattamaneni; J M Birch
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  Second primary neoplasms in patients with retinoblastoma.

Authors:  G J Draper; B M Sanders; J E Kingston
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more
  92 in total

1.  Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.

Authors:  Lindsay M Morton; Luisel Ricks-Santi; Catharine M L West; Barry S Rosenstein
Journal:  Int J Part Ther       Date:  2018-09-21

2.  Agenda for Translating Physical Activity, Nutrition, and Weight Management Interventions for Cancer Survivors into Clinical and Community Practice.

Authors:  Karen Basen-Engquist; Catherine M Alfano; Melissa Maitin-Shepard; Cynthia A Thomson; Kathryn H Schmitz; Bernardine M Pinto; Kevin Stein; David S Zucker; Karen L Syrjala; Elizabeth Fallon; Colleen Doyle; Wendy Demark-Wahnefried
Journal:  Obesity (Silver Spring)       Date:  2017-11       Impact factor: 5.002

3.  Incidence of second primary cancers in North Portugal-a population-based study.

Authors:  Luís Pacheco-Figueiredo; Luís Antunes; Maria José Bento; Nuno Lunet
Journal:  J Cancer Surviv       Date:  2015-07-10       Impact factor: 4.442

4.  Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.

Authors:  Miho Kono; Pamela K Allen; Steven H Lin; Xiong Wei; Melenda D Jeter; James W Welsh; James D Cox; Ritsuko Komaki
Journal:  J Thorac Oncol       Date:  2017-08-10       Impact factor: 15.609

5.  Second malignancies in patients with neuroblastoma: the effects of risk-based therapy.

Authors:  Mark A Applebaum; Tara O Henderson; Sang Mee Lee; Navin Pinto; Samuel L Volchenboum; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2014-09-23       Impact factor: 3.167

6.  The association between histological subtype of a first primary endometrial cancer and second cancer risk.

Authors:  Jennifer Rhoades; Monica Hagan Vetter; James L Fisher; David E Cohn; Ritu Salani; Ashley S Felix
Journal:  Int J Gynecol Cancer       Date:  2018-12-21       Impact factor: 3.437

7.  Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

Authors:  Joanne Ngeow; Kim Stanuch; Jessica L Mester; Jill S Barnholtz-Sloan; Charis Eng
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 8.  Accelerated Premalignant Polyposis and Second Colon Cancers: Incriminating Immunosuppression, Radiotherapy, and Systemic Chemotherapy Agents.

Authors:  Frank J Senatore; Shruti Murali; Constantin A Dasanu
Journal:  J Gastrointest Cancer       Date:  2016-06

Review 9.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

10.  NCCN Guidelines Insights: Survivorship, Version 2.2020.

Authors:  Crystal S Denlinger; Tara Sanft; Javid J Moslehi; Linda Overholser; Saro Armenian; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Norah Lynn Henry; Christine Hill-Kayser; Melissa Hudson; Nazanin Khakpour; Divya Koura; Allison L McDonough; Michelle Melisko; Kathi Mooney; Halle C F Moore; Natalie Moryl; Tracey O'Connor; Electra D Paskett; Chirayu Patel; Lindsay Peterson; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Lillie Shockney; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2020-08       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.